Tag Archives: Weight loss drug target

ActRII signaling pathway

ActRII – A Novel Drug Target that Preserves Skeletal Muscle Mass and Enhances Fat Loss

In the previous article, we focused on the popular drug target for weight loss, G Protein-Coupled Receptor 75 (GPR75). This time, our topic is another emerging target for treating adult obesity, Activin A Receptor Type 2 (ActRII). Unlike currently approved weight loss drugs, which can reduce the weight of obese patients but often lead to […]

Blog 2024-04-10
20-HETE Receptor (GPR75) Signaling in Endothelial Cells

GPR75 – An Emerging Target for Weight Loss Drugs

When it comes to weight loss medications, one cannot overlook the remarkable success of Semaglutide (GLP-1 weight loss drug), which has propelled the Danish biopharmaceutical company, Novo Nordisk, to new heights. According to Novo Nordisk’s financial report for 2023, Semaglutide sales reached $21.2 billion in 2023. On March 7th, Novo Nordisk’s stock price surged by […]

Blog 2024-04-01